378 related articles for article (PubMed ID: 19150547)
1. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Morgentaler A
J Urol; 2009 Mar; 181(3):972-9. PubMed ID: 19150547
[TBL] [Abstract][Full Text] [Related]
2. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Morgentaler A
J Urol; 2013 Jan; 189(1 Suppl):S26-33. PubMed ID: 23234627
[TBL] [Abstract][Full Text] [Related]
3. Testosterone therapy in men with untreated prostate cancer.
Morgentaler A; Lipshultz LI; Bennett R; Sweeney M; Avila D; Khera M
J Urol; 2011 Apr; 185(4):1256-60. PubMed ID: 21334649
[TBL] [Abstract][Full Text] [Related]
4. Testosterone and prostate cancer: revisiting old paradigms.
Isbarn H; Pinthus JH; Marks LS; Montorsi F; Morales A; Morgentaler A; Schulman C
Eur Urol; 2009 Jul; 56(1):48-56. PubMed ID: 19375844
[TBL] [Abstract][Full Text] [Related]
5. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
6. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.
Lane BR; Stephenson AJ; Magi-Galluzzi C; Lakin MM; Klein EA
Urology; 2008 Dec; 72(6):1240-5. PubMed ID: 18692874
[TBL] [Abstract][Full Text] [Related]
7. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
Kaufman JM; Graydon RJ
J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
[TBL] [Abstract][Full Text] [Related]
8. A new era of testosterone and prostate cancer: from physiology to clinical implications.
Khera M; Crawford D; Morales A; Salonia A; Morgentaler A
Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer in men using testosterone supplementation.
Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
[TBL] [Abstract][Full Text] [Related]
11. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
12. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
Morales A; Black AM; Emerson LE
BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
[TBL] [Abstract][Full Text] [Related]
13. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
15. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
16. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
Kaufman J
Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
[TBL] [Abstract][Full Text] [Related]
17. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement therapy after primary treatment for prostate cancer.
Agarwal PK; Oefelein MG
J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
[TBL] [Abstract][Full Text] [Related]
19. Reduced circulating androgen bioactivity in patients with prostate cancer.
Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
